421 related articles for article (PubMed ID: 17218210)
1. C-reactive protein: a nontraditional serum marker of cardiovascular risk.
de Ferranti SD; Rifai N
Cardiovasc Pathol; 2007; 16(1):14-21. PubMed ID: 17218210
[TBL] [Abstract][Full Text] [Related]
2. High sensitivity C-reactive protein in cardiovascular risk assessment. CRP mania or useful screening?
Sellmayer A; Limmert T; Hoffmann U
Int Angiol; 2003 Mar; 22(1):15-23. PubMed ID: 12771851
[TBL] [Abstract][Full Text] [Related]
3. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus.
Ridker PM
J Am Coll Cardiol; 2007 May; 49(21):2129-38. PubMed ID: 17531663
[TBL] [Abstract][Full Text] [Related]
4. Association of lipid and inflammatory markers with C-reactive protein in cardiovascular risk assessment for primary prevention.
Jovicić S; Ignjatović S; Dajak M; Kangrga R; Majkić-Singh N
Clin Lab; 2009; 55(11-12):411-9. PubMed ID: 20225663
[TBL] [Abstract][Full Text] [Related]
5. High-sensitivity C-reactive protein is only weakly related to cardiovascular damage after adjustment for traditional cardiovascular risk factors.
Olsen MH; Christensen MK; Hansen TW; Gustafsson F; Rasmussen S; Wachtell K; Borch-Johnsen K; Ibsen H; Jørgensen T; Hildebrandt P
J Hypertens; 2006 Apr; 24(4):655-61. PubMed ID: 16531793
[TBL] [Abstract][Full Text] [Related]
6. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk?
Ridker PM; Wilson PW; Grundy SM
Circulation; 2004 Jun; 109(23):2818-25. PubMed ID: 15197153
[TBL] [Abstract][Full Text] [Related]
7. The novel role of C-reactive protein in cardiovascular disease: risk marker or pathogen.
Wilson AM; Ryan MC; Boyle AJ
Int J Cardiol; 2006 Jan; 106(3):291-7. PubMed ID: 16337036
[TBL] [Abstract][Full Text] [Related]
8. High-sensitivity C-reactive protein: clinical importance.
Bassuk SS; Rifai N; Ridker PM
Curr Probl Cardiol; 2004 Aug; 29(8):439-93. PubMed ID: 15258556
[TBL] [Abstract][Full Text] [Related]
9. Significance of a multiple biomarkers strategy including endothelial dysfunction to improve risk stratification for cardiovascular events in patients at high risk for coronary heart disease.
Nozaki T; Sugiyama S; Koga H; Sugamura K; Ohba K; Matsuzawa Y; Sumida H; Matsui K; Jinnouchi H; Ogawa H
J Am Coll Cardiol; 2009 Aug; 54(7):601-8. PubMed ID: 19660689
[TBL] [Abstract][Full Text] [Related]
10. High-sensitivity C-reactive protein and cardiovascular disease: a resolute belief or an elusive link?
Yousuf O; Mohanty BD; Martin SS; Joshi PH; Blaha MJ; Nasir K; Blumenthal RS; Budoff MJ
J Am Coll Cardiol; 2013 Jul; 62(5):397-408. PubMed ID: 23727085
[TBL] [Abstract][Full Text] [Related]
11. C-reactive protein: a novel marker of cardiovascular risk.
Shah SH; Newby LK
Cardiol Rev; 2003; 11(4):169-79. PubMed ID: 12852794
[TBL] [Abstract][Full Text] [Related]
12. Inflammation in atherothrombosis: how to use high-sensitivity C-reactive protein (hsCRP) in clinical practice.
Ridker PM
Am Heart Hosp J; 2004; 2(4 Suppl 1):4-9. PubMed ID: 15539969
[TBL] [Abstract][Full Text] [Related]
13. Preventive cardiology: move over low density lipoprotein cholesterol, hello C-reactive protein?
Genest J
Can J Cardiol; 2004 Aug; 20 Suppl B():89B-92B. PubMed ID: 15309211
[TBL] [Abstract][Full Text] [Related]
14. High sensitivity C-reactive protein and cardiovascular disease: an association built on unstable foundations?
Sattar N; Lowe GD
Ann Clin Biochem; 2006 Jul; 43(Pt 4):252-6. PubMed ID: 16824274
[TBL] [Abstract][Full Text] [Related]
15. C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular diseases.
Li JJ; Fang CH
Med Hypotheses; 2004; 62(4):499-506. PubMed ID: 15050096
[TBL] [Abstract][Full Text] [Related]
16. C-reactive protein: a new golden marker of cardiovascular risk.
Gomes MC
Rev Port Cardiol; 2002 Nov; 21(11):1329-46. PubMed ID: 12564084
[TBL] [Abstract][Full Text] [Related]
17. [C-reactive protein in cardiovascular risk evaluation].
Fabijanić D; Banić M; Kardum D
Lijec Vjesn; 2006; 128(5-6):167-74. PubMed ID: 16910418
[TBL] [Abstract][Full Text] [Related]
18. Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker.
Corson MA; Jones PH; Davidson MH
Am J Cardiol; 2008 Jun; 101(12A):41F-50F. PubMed ID: 18549871
[TBL] [Abstract][Full Text] [Related]
19. [Inflammation and C-reactive protein in cardiovascular disease].
Munk PS; Larsen AI
Tidsskr Nor Laegeforen; 2009 Jun; 129(12):1221-4. PubMed ID: 19521445
[TBL] [Abstract][Full Text] [Related]
20. Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham Risk Scores.
Ridker PM; Cook N
Circulation; 2004 Apr; 109(16):1955-9. PubMed ID: 15051634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
